Integrating multi-modal deep learning on knowledge graph for the discovery of synergistic drug combinations against infectious diseases
Source abstract
Abstract
The threat to global health posed by unpredictable infections and increasing antimicrobial resistance necessitates the urgent development of drug combination therapies (DCBs) for infectious diseases. Substantial efforts have been devoted to perfecting predictions for DCBs, but data scarcity and poor model interpretability continue to present significant barriers to the development of novel DCBs. To address these issues, here we propose a framework for predicting DCBs by combining knowledge graph representation learning and the technique of community discovery for complex networks. Within this framework, we demonstrate that multi-modal information and multiple types of DCBs could significantly facilitate the predictive performance and improve hit rates in realistic virtual screening scenarios. The high hit rate of 85% for experimental validation strongly supports the proposal that our approach could effectively harness useful information hidden in highly complex biological networks and accelerate in silico discovery of pairwise DCBs for infectious diseases and beyond.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Computational Drug Discovery Methods · Bioinformatics and Genomic Networks · Machine Learning in Bioinformatics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (72)
Show source-provided references
1. Discovering protein drug targets using knowledge graph embeddings10.1093/bioinformatics/btz600 ↗
2. Contexts and contradictions: a roadmap for computational drug repurposing with knowledge inference10.1093/bib/bbac268 ↗
3. Biological applications of knowledge graph embedding models10.1093/bib/bbaa012 ↗
4. A comprehensive SARS-CoV-2-human protein-protein interactome reveals COVID-19 pathobiology and potential host therapeutic targets10.1038/s41587-022-01474-0 ↗
5. Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer10.1038/s41467-022-29292-7 ↗
6. Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease10.1038/s43587-021-00138-z ↗
7. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis10.1016/S0140-6736(21)02724-0 ↗
8. O'Neill · 2016
9. Drug repurposing screens and synergistic drug-combinations for infectious diseases10.1111/bph.13895 ↗
10. Drug combination therapy increases successful drug repositioning10.1016/j.drudis.2016.05.015 ↗
11. A robustness-based approach to systems-oriented drug design10.1038/nrd2195 ↗
12. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells10.1073/pnas.1311846111 ↗
13. Patient-derived models of acquired resistance can identify effective drug combinations for cancer10.1126/science.1254721 ↗
14. Methods for high-throughput drug combination screening and synergy scoring
15. Machine learning to design antimicrobial combination therapies: promises and pitfalls10.1016/j.drudis.2022.04.006 ↗
16. Prediction of antibiotic interactions using descriptors derived from molecular structure10.1021/acs.jmedchem.7b00204 ↗
17. Using machine learning to predict synergistic antimalarial compound combinations with novel structures10.3389/fphar.2018.01096 ↗
18. Qsar modeling and prediction of drug–drug interactions10.1021/acs.molpharmaceut.5b00762 ↗
19. Synergistic and antagonistic drug combinations against SARS-CoV-210.1016/j.ymthe.2020.12.016 ↗
20. Comparative analysis of molecular fingerprints in prediction of drug combination effects10.1093/bib/bbab291 ↗
21. Deep learning identifies synergistic drug combinations for treating COVID-1910.1073/pnas.2105070118 ↗
22. Prediction of effective drug combinations by an improved naïve bayesian algorithm10.3390/ijms19020467 ↗
23. Prediction of drug combinations by integrating molecular and pharmacological data10.1371/journal.pcbi.1002323 ↗
24. Network-based prediction of drug combinations10.1038/s41467-019-09186-x ↗
25. Incorporating Multisource Knowledge To Predict Drug Synergy Based on Graph Co-regularization10.1021/acs.jcim.9b00793 ↗
26. What are the current challenges for machine learning in drug discovery and repurposing?10.1080/17460441.2022.2050694 ↗
27. Neighbor communities in drug combination networks characterize synergistic effect10.1039/c2mb25267h ↗
28. Chemogenomics and orthology-based design of antibiotic combination therapies10.15252/msb.20156777 ↗
29. CDCDB: A large and continuously updated drug combination database10.1038/s41597-022-01360-z ↗
30. Overlapping community detection using seed set expansion
31. Local Graph Partitioning Using Pagerank Vectors
32. Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery10.1021/acs.molpharmaceut.8b00083 ↗
33. Mechanisms of drug combinations: interaction and network perspectives10.1038/nrd2683 ↗
34. Recover: sequential model optimization platform for combination drug repurposing identifies novel synergistic compounds in vitro
35. Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis10.1126/sciadv.1701881 ↗
36. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis10.1378/chest.99.4.1025 ↗
37. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB
38. The Use of Ethionamide in Combined Drug Regimens in the Re-treatment of Isoniazid-Resistant Pulmonary Tuberculosis
39. Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis10.1128/AAC.38.10.2346 ↗
40. Synergistic effect of rifampin, streptomycin, ethionamide, and ethambutol on Mycobacterium intracellulare
41. Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections10.1164/ajrccm/136.2.329 ↗
42. Treatment-shortening effect of a novel regimen combining clofazimine and high-dose rifapentine in pathologically distinct mouse models of tuberculosis10.1128/AAC.00388-19 ↗
43. Species-specific activity of antibacterial drug combinations10.1038/s41586-018-0278-9 ↗
44. Systematic exploration of synergistic drug pairs10.1038/msb.2011.71 ↗
45. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients10.1164/ajrccm.160.1.9901063 ↗
46. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations10.1016/j.jaci.2015.09.008 ↗
47. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD10.1016/j.rmed.2008.12.014 ↗
48. Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension10.1517/14656560903124388 ↗
49. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma10.1136/bjo.2008.155317 ↗
50. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study10.1002/cncr.26204 ↗
51. Comparison of docetaxel and docetaxel–irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial10.1093/annonc/mdi053 ↗
52. Therapeutic implications of hypertension-induced glomerular injury: comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model10.1016/0002-9343(85)90078-6 ↗
53. Methyldopa and hydrochlorothiazide in primary hypertension: controlled clinical trial of drugs singly and in combination10.1001/jama.1963.03060110023012 ↗
54. The influence of perindopril and the diuretic combination amiloride+ hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients10.1097/00004872-199508000-00004 ↗
55. Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information10.1093/nar/gkv1230 ↗
56. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing10.1038/s41586-020-2577-1 ↗
57. Systematic identification of synergistic drug pairs targeting HIV10.1038/nbt.2391 ↗
58. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing10.1038/s41586-020-2286-9 ↗
59. Turning the respiratory flexibility of Mycobacterium tuberculosis against itself10.1038/ncomms12393 ↗
60. In vitro and in vivo synergistic effect of isoniazid with streptomycin and clofazimine against Mycobacterium avium complex (MAC)10.1016/0962-8479(94)90010-8 ↗
61. Repurposing clinically approved cephalosporins for tuberculosis therapy10.1038/srep34293 ↗
62. Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis10.1126/sciadv.1701102 ↗
63. Towards a new combination therapy for tuberculosis with next generation benzothiazinones10.1002/emmm.201303575 ↗
64. Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis10.1016/j.cels.2021.08.004 ↗
65. Representation learning for attributed multiplex heterogeneous network
66. metapath2vec: Scalable representation learning for heterogeneous networks
67. A three-way model for collective learning on multi-relational data
68. Complex embeddings for simple link prediction
69. Scikit-learn: Machine learning in Python
70. DeepPurpose: a deep learning library for drug–target interaction prediction10.1093/bioinformatics/btaa1005 ↗
71. Akiba · 2019 · 2623
72. CDLIB: a python library to extract, compare and evaluate communities from complex networks10.1007/s41109-019-0165-9 ↗